 JERUSALEM, Oct. 19, 2021 PRNewswire -- BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signing of a term sheet that includes binding financial terms of contemplated definitive agreements with the Max Planck Society and the University Medical Center Göttingen in Germany. 